CA3086337A1 - Gpcr heteromer inhibitors and uses thereof - Google Patents

Gpcr heteromer inhibitors and uses thereof Download PDF

Info

Publication number
CA3086337A1
CA3086337A1 CA3086337A CA3086337A CA3086337A1 CA 3086337 A1 CA3086337 A1 CA 3086337A1 CA 3086337 A CA3086337 A CA 3086337A CA 3086337 A CA3086337 A CA 3086337A CA 3086337 A1 CA3086337 A1 CA 3086337A1
Authority
CA
Canada
Prior art keywords
cxcr4
gpcrx
inhibitor
treating
heteromer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3086337A
Other languages
English (en)
French (fr)
Inventor
Dongseung Seen
Eunhee Kim
Jae-Yeon Jeong
Chang Soo Yang
Milim LEE
Sohui Kim
Won-Ki Huh
Yong Bhum Song
Chul O Park
Hyeryung Park
Jiyeong Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GPCR Therapeutics Inc
Original Assignee
GPCR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GPCR Therapeutics Inc filed Critical GPCR Therapeutics Inc
Publication of CA3086337A1 publication Critical patent/CA3086337A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
CA3086337A 2017-12-19 2018-12-18 Gpcr heteromer inhibitors and uses thereof Pending CA3086337A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762607876P 2017-12-19 2017-12-19
US62/607,876 2017-12-19
US201862679598P 2018-06-01 2018-06-01
US62/679,598 2018-06-01
US201862732946P 2018-09-18 2018-09-18
US62/732,946 2018-09-18
PCT/KR2018/016166 WO2019124951A1 (en) 2017-12-19 2018-12-18 Gpcr heteromer inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3086337A1 true CA3086337A1 (en) 2019-06-27

Family

ID=66813757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3086337A Pending CA3086337A1 (en) 2017-12-19 2018-12-18 Gpcr heteromer inhibitors and uses thereof

Country Status (10)

Country Link
US (3) US10709763B2 (cg-RX-API-DMAC7.html)
EP (2) EP3900712A1 (cg-RX-API-DMAC7.html)
JP (2) JP7517986B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200103018A (cg-RX-API-DMAC7.html)
CN (1) CN111741752A (cg-RX-API-DMAC7.html)
AU (1) AU2018388302B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086337A1 (cg-RX-API-DMAC7.html)
TW (1) TWI818938B (cg-RX-API-DMAC7.html)
WO (1) WO2019124951A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
KR20220078526A (ko) * 2019-03-06 2022-06-10 인메드 파마슈티컬스 인코포레이티드 이종 시스템에서 테르페노이드 또는 칸나비노이드의 생합성을 위한 조성물 및 방법
KR20210156849A (ko) * 2019-05-17 2021-12-27 주식회사 지피씨알 Gpcr 헤테로머 저해제들 및 이의 용도
KR102268983B1 (ko) * 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN110755431B (zh) * 2019-11-08 2023-02-28 暨南大学 地氯雷他定在制备抗肝癌药物中的应用
JPWO2022025168A1 (cg-RX-API-DMAC7.html) * 2020-07-30 2022-02-03
EP4196611A1 (en) 2020-08-15 2023-06-21 Regeneron Pharmaceuticals, Inc. Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr)
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
EP4306655A4 (en) * 2021-08-04 2024-08-21 Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
WO2023211779A1 (en) * 2022-04-25 2023-11-02 Kallyope, Inc. Treatment of headache disorders with nk3 modulators
AU2023285050A1 (en) * 2022-06-10 2025-01-23 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
CN114891742B (zh) * 2022-06-23 2024-06-04 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法
CN116298305B (zh) * 2023-01-03 2024-05-28 郑州大学 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒
KR20260011143A (ko) 2023-04-18 2026-01-22 칼리오페, 인크. Nk3 조정제 및 이의 용도
AU2024334309A1 (en) * 2023-08-30 2026-03-05 Josephine Cardarelli Gpcr inhibitors and uses thereof
CN119345201B (zh) * 2024-12-25 2025-03-18 中国人民解放军总医院第三医学中心 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000538A2 (en) 1996-07-01 1998-01-08 Biosignal Inc. Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization
AU3249997A (en) 1996-07-01 1998-01-21 Biosignal Inc. Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization
US6855807B1 (en) 1999-06-16 2005-02-15 New York University Heterodimeric opioid G-protein coupled receptors
US20010053848A1 (en) 2000-03-10 2001-12-20 Patel Yogesh C. Hetero-oligomeric G protein-coupled receptors as novel drug targets
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1625159B1 (en) 2003-05-20 2011-03-02 The University Court Of The University Of Glasgow Materials and methods relating to g-protein coupled receptor oligomers
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
CA2640087A1 (en) * 2006-01-25 2007-08-02 Mount Sinai School Of Medicine Methods and compositions for modulating the mobilization of stem cells
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010002468A1 (en) 2008-07-01 2010-01-07 The Trustees Of Columbia University In The City Of New York A functional complementation assay for defined gpcr oligomers
FR2949156B1 (fr) 2009-08-13 2016-04-15 Cis-Bio Int Methode de determination de la liaison d'un compose donne a un recepteur membranaire
WO2011091435A2 (en) 2010-01-25 2011-07-28 Mount Sinai School Of Medicine Methods of treating liver disease
JP2011168567A (ja) * 2010-02-22 2011-09-01 Kyoto Univ 再発癌の予防または治療用医薬
KR101029972B1 (ko) 2010-06-18 2011-04-20 서울대학교산학협력단 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법
WO2012047339A2 (en) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
US9267934B2 (en) * 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
MX371455B (es) * 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
WO2015095973A1 (en) 2013-12-23 2015-07-02 Université de Montréal Systems and methods for the monitoring of protein complex formation in cells
DK3242685T3 (da) * 2015-01-09 2022-07-25 Adalta Ltd Cxcr4-bindende molekyler
WO2017020128A1 (en) * 2015-08-03 2017-02-09 Université de Montréal Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도

Also Published As

Publication number Publication date
AU2018388302A1 (en) 2020-07-02
JP7517986B2 (ja) 2024-07-17
US10709763B2 (en) 2020-07-14
KR20200103018A (ko) 2020-09-01
CN111741752A (zh) 2020-10-02
EP3727371A4 (en) 2021-10-27
JP2021507925A (ja) 2021-02-25
TW202017598A (zh) 2020-05-16
BR112020012075A2 (pt) 2020-12-01
AU2018388302B2 (en) 2024-10-31
TWI818938B (zh) 2023-10-21
WO2019124951A9 (en) 2019-11-07
US20210268069A1 (en) 2021-09-02
EP3727371A1 (en) 2020-10-28
KR20260035212A (ko) 2026-03-12
US20200360478A1 (en) 2020-11-19
WO2019124951A1 (en) 2019-06-27
JP2024109616A (ja) 2024-08-14
EP3900712A1 (en) 2021-10-27
JP7818648B2 (ja) 2026-02-20
US11857600B2 (en) 2024-01-02
US20190183976A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
US11857600B2 (en) GPCR heteromer inhibitors and uses thereof
Alampour‐Rajabi et al. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP‐70 signaling, and lymphocyte chemotaxis
CN106536556B (zh) 结合lgr5的人源化抗体
CN104105702B (zh) 人notch受体突变及其应用
US20170234879A1 (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
KR101798664B1 (ko) 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제
RS53405B (sr) Humanizovana antitela na cxcr4 za lečenje kancera
WO2018199318A1 (ja) 抗gpc-1抗体
JPWO2016133059A1 (ja) Fstl1を利用した抗がん剤・転移抑制剤およびその併用剤
Jackson et al. Novel bispecific domain antibody to LRP6 inhibits Wnt and R-spondin ligand-induced Wnt signaling and tumor growth
JP7561631B2 (ja) 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗cxcr4抗体
CN117794571A (zh) 抗癌和免疫增强的新靶点
KR20140014062A (ko) 항-에프린 b2 항체 및 이의 용도
AU2020278977B2 (en) GPCR heteromer inhibitors and uses thereof
HK40062725A (en) Gpcr heteromer inhibitors and uses thereof
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
AU2024334309A1 (en) Gpcr inhibitors and uses thereof
JP7621972B2 (ja) 新規な選択的ackr3調節性物質及びその使用
Crawford et al. Prospects for targeting ACKR1 in
US20220267390A1 (en) Mps modified peptides and use thereof
CN119744268A (zh) 靶向pd-l1降解

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250523

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250602

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251024

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251117

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260225

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260225